<DOC>
	<DOCNO>NCT01082406</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial compare metabolism blood-clotting drug ( recombinant Factor XIII ) ) produce two different manufacturer ( Novo Nordisk Avecia ) healthy male volunteer .</brief_summary>
	<brief_title>Comparison Blood Clotting Drug ( Recombinant Factor XIII ) Produced Two Different Manufacturers Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Body Mass Index ( BMI ) 18.5 30 kg/m2 Good general health base assessment medical history , physical examination , ECG ( electrocardiogram ) , clinical laboratory data screening , judge physician Nonsmokers Known history thromboembolic event ( ) potential thromboembolic risk judge physician Blood transfusion within 3 month trial start Positive hepatitis B C infection Positive Human Immunodeficiency Virus ( HIV ) infection Excessive consumption diet deviate normal diet judge physician Blood plasma donation within last 3 month prior trial start Subjects history migraine</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>